Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma is a research paper published in Cancer Medicine (2024). On theSindex it has a DataRank of 0.450. It has been cited 12 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
0.0648
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
National Institutes of Health
Grant: ZIA BC 011343
Cholangiocarcinoma Foundation
Fields of Study
MeSH Terms
Keywords